Joel Myers Harris

US Patent:

20100114225, May 6, 2010

Filed:

Nov 5, 2008

Appl. No.:

12/265690

Inventors:

Mir Imran - Los Altos Hills CA, US
Dean Andersen - San Jose CA, US
Joel Harris - Mountain View CA, US

International Classification:

H05K 5/06
A61N 1/00

US Classification:

607 9, 174 5052

Abstract:

Embodiments described herein provide lid structures for medical implant (MI) housing. In one embodiment, the invention provides a lid structure for a MI housing comprising a substrate comprising a dielectric material, a conductive portion fabricated on a substrate surface or interior, a frame at least partially surrounding the substrate perimeter, a plurality of vias projecting at least partially through the substrate, a plurality of conductive pins with at least one pin projecting through a via. The frame is hermetically joined to the substrate and can be hermetically joined to the housing. The conductive portion allows electrical components, including capacitors, inductors, resistor and antennas to be fabricated on or coupled to the substrate surface or interior. The antenna comprises a conductive trace positioned on a substrate top surface and is configured to send and receive signals between an implant within a patient's body and a communication device external to the body.

US Patent:

20100191305, Jul 29, 2010

Filed:

Jan 26, 2009

Appl. No.:

12/359830

Inventors:

Mir Imran - Los Altos Hills CA, US
Lu Wang - Menlo Park CA, US
Paren Shah - Mountain View CA, US
Joel Harris - Mountain View CA, US

International Classification:

A61N 1/36
A61B 5/0478
A61M 5/00

US Classification:

607 45, 600544, 604500

Abstract:

Embodiments provide an apparatus and method for detection of aberrant neural-electric activity (ANEA) in the brain causing an epileptic seizure or other neurologic condition. One embodiment provides an apparatus for detection of ANEA comprising an introducer having at least one lumen. The introducer is introduced into brain tissue through an opening in the skull. A reference electrode is positioned at an introducer distal portion. A plurality of electrode members are advanceable within the at least one lumen with each member having an insulated portion and an exposed distal portion. The members have a non-deployed state in the introducer and a deployed state when outwardly advanced out of the introducer. In the deployed state, the members are substantially orthogonal to each other with the exposed distal portions defining a detection volume capable of determining an electric field vector produced by the ANEA and the direction of a foci of the ANEA.

US Patent:

20100268295, Oct 21, 2010

Filed:

Apr 21, 2009

Appl. No.:

12/427733

Inventors:

Mir Imran - Los Altos Hills CA, US
Joel Harris - Mountain View CA, US

International Classification:

A61N 1/365

US Classification:

607 14

Abstract:

An embodiment of the invention provides an apparatus for the detection and treatment of atrial arrhythmia comprising an electrical lead having proximal and distal portions. The distal portion is positionable in an atrial chamber and the end of the proximal portion is configured to be coupled to a pacemaker. The lead comprises a plurality of conductive wires clad with an insulative coating and has sufficient flexibility to be positioned in the atria from a percutaneous introductory site. The conductive wires are coupled to a plurality of pairs of bipolar electrodes positioned on a membrane attachable to an endocardial wall. The electrode pairs are distributed in a pattern defining an area for detecting a location of a foci of aberrant electrical activity located within or adjacent the area and sending a pacing signal to that location to prevent or stop an occurrence of atrial fibrillation caused by that foci.

US Patent:

20120177700, Jul 12, 2012

Filed:

Dec 27, 2011

Appl. No.:

13/338210

Inventors:

Mir A. Imran - Los Altos Hills CA, US
Mir Hashim - Fremont CA, US
Lu Wang - San Jose CA, US
Sanjay Patel - Palo Alto CA, US
Joel M. Harris - Mountain View CA, US
Phil Morgan - San Antonio TX, US

International Classification:

A61K 9/00
A61K 33/42
B82Y 5/00

US Classification:

424400, 424604, 977773, 977915

Abstract:

Embodiments of the invention provide nanonized iron compositions for treatment of iron deficiency such as iron deficiency anemia. Many embodiments provide nanonized iron compositions which are sized to minimize adverse reaction such as immune response, adverse GI reaction and allergic reaction to iron compound included in the composition. The nanonized iron compositions can be used in a variety of drug delivery forms, including an oral dosage form, a transdermal patch, in an intravenous solution or in a dialysate for treatment of a patient with chronic kidney disease (CKD). Embodiments of the invention also provide methods of using the nanonized iron compositions for the treatment of iron deficiency in a patient in need thereof including patients with iron deficiency anemia and CKD.

US Patent:

20120184894, Jul 19, 2012

Filed:

Jan 3, 2012

Appl. No.:

13/342948

Inventors:

Mir Imran - Los Altos Hills CA, US
Phil Morgan - San Antonio TX, US
Mir Hashim - Fremont CA, US
Joel Harris - Mountain View CA, US

International Classification:

A61N 1/30

US Classification:

604 20

Abstract:

Embodiments of the invention provide patches for the transdermal delivery of compositions to treat an individual suffering from hair loss. Many embodiments provide an iontophoretic patch for the transdermal delivery hair growth stimulating agents for the treatment of hair loss by stimulating the growth of new hair in areas of the scalp exhibiting hair loss. The patch comprises an electrode and a reservoir containing a composition comprising iron containing compound, such as a chelated iron compound for the delivery of the therapeutically effective amount of iron. The patch can be shaped to be placed and remain on the head. Various embodiments provide methods of using embodiments of the iontophoretic patch for delivering a hair growth stimulating agent such as a chelated iron compound, minoxidil and finasteride to the scalp and other areas exhibiting hair loss. Such methods can be used for re-growing hair, and/or preventing or slowing hair loss.

US Patent:

20130023815, Jan 24, 2013

Filed:

Mar 26, 2012

Appl. No.:

13/430662

Inventors:

Mir Imran - Los Altos Hills CA, US
Mir Hashim - Fremont CA, US
Glen McLaughlin - San Carlos CA, US
Huma Arastu - San Jose CA, US
Rekha Vaidyanathan - San Jose CA, US
Joel Harris - Mountain View CA, US
Radhika Korupolu - San Jose CA, US
Andrew Mangogna - San Jose CA, US
Chang Ong - San Jose CA, US
Sanjay Patel - San Jose CA, US
Lu Wang - San Jose CA, US
Timothy Williams - San Jose CA, US

International Classification:

A61N 1/30

US Classification:

604 20, 604501

Abstract:

Various embodiments provide methods and systems for the biphasic iontophoretic transdermal delivery of therapeutic agents. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient. Embodiments may be used for delivery of agents which cause adverse effects from unwanted passive diffusion.

US Patent:

20130325108, Dec 5, 2013

Filed:

Jun 1, 2010

Appl. No.:

13/261054

Inventors:

Mir Imran - Los Altos Hills CA, US
Sanjay Patel - Palo Alto CA, US
Joel Harris - Mountain View CA, US

International Classification:

A61L 27/14
A61F 2/04
A61F 2/82

US Classification:

623 138, 623 2375, 623 237, 623 2372

Abstract:

Embodiments of the invention provide compositions comprising bio degradable polymers, medical implants fabricated from these compositions and methods of using such implants. Many embodiments provide medical implants comprising a first polymer backbone having a first rate of biodegradation and a second polymer backbone having a second rate of biodegradation faster than the first rate. In some embodiments, the second backbone is configured to be replaced by a natural tissue layer. The first backbone provides a scaffold for the implant while the second backbone degrades. This scaffold can enhance mechanical properties of the implant including various aspects of mechanical strength such as tensile, bending, hoop and yield strength; and elasticity. The scaffold also serves to maintain a minimum level of structural support of the implant during the period of degradation of the second backbone or for the entire life of the implant so that the implant does not mechanically fail.

US Patent:

20230061375, Mar 2, 2023

Filed:

Nov 8, 2022

Appl. No.:

17/982788

Inventors:

- San Jose CA, US
Joel HARRIS - Mountain View CA, US

International Classification:

A61K 9/48
A61K 35/12
A61K 9/00
A61B 5/00
A61B 5/145
A61M 31/00
A61K 35/28
A61K 35/30
A61K 35/39
A61K 9/06
A61M 25/10

Abstract:

Embodiments provide swallowable devices, preparations and methods for delivering viable cells (VC) into the GI tract including GI wall tissue or other tissue site. Particular embodiments provide a swallowable device such as a capsule for delivering VC into an intestinal wall or other site. The VC can be contained within a tissue-penetrating shell disposed in the capsule that protects the VC as they pass through the GI tract until they are inserted into GI tract tissue or other location. The shell desirably has shape, size and material consistency to be contained in a swallowable capsule, delivered from the capsule into solid tissue by the application of force on the shell and biodegrade within the solid tissue to release the VC into the tissue. Within the shell or other structure the VC can be maintained in a viability-sustaining gel that preserves the viability of the VC for selected time periods.